Leveraging innate cell engagers for lymphoma treatment
European Pharmaceutical Review
DECEMBER 28, 2023
These efficacy results, combined with the safety profile that allows patients to complete their treatment regimen, are extremely encouraging. The majority of patients experienced only mild to moderate treatment-related adverse events, confirming a well-manageable safety profile. later acquired by Eli Lilly and Company.
Let's personalize your content